Prussian Blue (ferric hexacyanoferrate (II)) for Treatment of Internal Contamination with Thallium or Radioactive Cesium

FDA has approved Radiogardase, also known as Prussian blue, for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

• FDA approves the first New Drug Application for treatment of radiation contamination. FDA News
• Prussian Blue Approval Letter (PDF - 30KB)
• Radiogardase Labeling
• Questions and Answers on Prussian Blue
• FDA Encourages New Drug Application Submissions For Prussian Blue As A Treatment For Thallium Or Radioactive Cesium Contamination (FDA Press Release)
• FDA Encourages New Applications for Drugs to Treat Internal Contamination from Radioactive Elements (FDA Press Release)

• Federal Register Notice: Guidance for Industry on Prussian Blue for Treatment of Internal Contamination with Thallium or Radioactive Cesium; Availability (Optional version: PDF - 49KB) 
• Guidance for Industry: Prussian Blue Drug Products--Submitting a New Drug Application (PDF - 178KB)
• Guidance for Industry: Internal Radioactive Contamination - Development of Decorporation Agents (PDF - 177KB)